Intellia Therapeutics, Inc. (NTLA)

Market Cap	1.64B +31.7%
Revenue (ttm)	67.67M +16.9%
Net Income	-412.69M
EPS	-3.81
Shares Out	118.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,010,396
Open	13.25
Previous Close	13.44
Day's Range	13.07 - 14.15
52-Week Range	5.90 - 28.25
Beta	2.02
Analysts	Buy
Price Target	20.45 (+47.02%)
Earnings Date	Feb 26, 2026

About NTLA

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an alloge...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2016
• Employees: 377
• Stock Exchange: NASDAQ
• Ticker Symbol: NTLA
• Website: https://www.intelliatx.com

Financial Performance

In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.

Analyst Summary

According to 20 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $20.45, which is an increase of 47.02% from the latest price.

Price Target

$20.45

(47.02% upside)

Analyst Consensus: Buy